Form 8-K - Current report:
SEC Accession No. 0001104659-25-071009
Filing Date
2025-07-28
Accepted
2025-07-28 07:37:31
Documents
16
Period of Report
2025-07-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2521829d1_8k.htm   iXBRL 8-K 38931
2 EXHIBIT 2.1 tm2521829d1_ex2-1.htm EX-2.1 568734
3 EXHIBIT 99.1 tm2521829d1_ex99-1.htm EX-99.1 14278
7 GRAPHIC tm2521829d1_ex99-1img01.jpg GRAPHIC 6621
8 GRAPHIC tm2521829d1_ex99-1img02.jpg GRAPHIC 3064
  Complete submission text file 0001104659-25-071009.txt   935139

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA adap-20250727.xsd EX-101.SCH 3023
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE adap-20250727_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE adap-20250727_pre.xml EX-101.PRE 22364
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2521829d1_8k_htm.xml XML 3747
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 251152952
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)